Targeting The Nuclear Factor Kappa-B (NF-κB) Pathway for Drug Discovery
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 April 2025 | Viewed by 1515
Special Issue Editor
Special Issue Information
Dear Colleagues,
Attenuation of the chronic inflammation caused by the dysregulated NF-κB signaling pathway under pathological conditions has been shown to be beneficial for the treatment of many common human diseases such as metabolic diseases associated with overnutrition, autoimmune diseases, and cancer. In cells, activation of NF-kappaB transcription factors requires the sequential activation of many signaling components including those from cell membrane receptors such as TNFRs, TLRs, IL1R, etc., receptor adaptor proteins, the ubiquitination–proteasome system, IkappaB kinase, and other protein kinases and regulatory proteins. In the past two decades, the growing interest in targeting different signaling components to mitigate over-activated NF-κB activities under disease conditions has resulted in the identification of many inhibitors for disease treatment. In this special Issue, we invite authors in this field to report their original research discoveries or review articles pertaining to novel therapeutic approaches for targeting the signaling proteins in the NF-kappaB pathway. We are especially interested in approaches that place consideration on avoiding the side effects of overly inhibiting the inflammatory response due to induced apoptosis and IL-1β secretion.
Dr. Guozhou Xu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NF-κB
- TNFR
- TLR
- IL1R
- receptor adaptor proteins
- IRAK
- c-IAP
- AKT IKK
- ubiquitin-proteasome system
- inflammatory response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
